SCHEMBL13620670

SCHEMBL13620670

CC(=O)Oc1ccc2cc(C=O)c(=O)oc2c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 9/20 0.62
GLA P06280 8/20 0.62
GAA P10253 7/20 0.62
ALDH1A1 P00352 7/20 0.62
HPGD P15428 5/20 0.62
HSD17B10 Q99714 4/20 0.62
CASP1 P29466 3/20 0.62
CASP7 P55210 3/20 0.62
CA12 O43570 3/20 0.61
CA9 Q16790 3/20 0.61
POLB P06746 2/20 0.61
TDP1 Q9NUW8 1/20 0.61
NPC1 O15118 3/20 0.61
RAB9A P51151 3/20 0.61
MEN1 O00255 2/20 0.61
KMT2A Q03164 2/20 0.61
CA2 P00918 1/20 0.54
MAPT P10636 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
GAPDH P04406 2/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11151090 0.82 CA12 (0.56) KDM4EGLAGAAALDH1A1HPGD
SCHEMBL6967029 0.82 ALDH1A1 (0.58) KDM4EGLAGAAALDH1A1HPGD
SCHEMBL4769996 0.81 KDM4E (0.67) KDM4EGLAGAAALDH1A1HPGD
SCHEMBL7884546 0.80 KDM4E (0.65) KDM4EGLAGAAALDH1A1HPGD
SCHEMBL29378625 0.80 KDM4E (0.65) KDM4EGLAGAAALDH1A1HPGD
SCHEMBL557449 0.80 KDM4E (0.65) KDM4EGLAGAAALDH1A1HPGD
SCHEMBL5940913 0.80 GAA (0.76) KDM4EGLAGAAALDH1A1HPGD
SCHEMBL26987584 0.80 KDM4E (0.52) KDM4EGLAGAAALDH1A1HPGD
SCHEMBL4101829 0.79 SLC16A3 (0.74) KDM4EGLAGAAALDH1A1HPGD
SCHEMBL2336577 0.78 KDM4E (0.62) KDM4EGLAGAAALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250381202-A1 PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY ZOUNEK ALEX (DE) 2025-12-18 US disclosed
WO-2025125335-A1 CYTOTOXIC OR RADIOPHARMACEUTICAL COMPOUND WITH SULFUR FLUORIDE EXCHANGE GROUP RADIOVAXX GMBH (DE) 2025-06-19 WO disclosed
EP-4551565-A1 PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY Zounek, Alex (DE) 2025-05-14 EP disclosed
WO-2024008833-A1 PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY ZOUNEK ALEX (DE) 2024-01-11 WO disclosed
WO-2024008833-A1 PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY ZOUNEK ALEX (DE) 2024-01-11 WO disclosed
EP-1204430-B1 CONJUGATES AND METHODS FOR THE PRODUCTION THEREOF, AND THEIR USE FOR TRANSPORTING MOLECULES VIA BIOLOGICAL MEMBRANES SANOFI AVENTIS DEUTSCHLAND (DE) 2009-11-04 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250381202-A1 PRODRUG KIT FOR MULTI-PRONGED CHEMOTHERAPY KIT, CTSL, PAICS KDM4E 2995/4885GLA 1153/4885GAA 1164/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.